Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina.

Zhang J, Long M, Yu Y.

J Thorac Dis. 2017 May;9(5):1226-1233. doi: 10.21037/jtd.2017.03.186.

2.

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.

Glerup S, Schulz R, Laufs U, Schlüter KD.

Basic Res Cardiol. 2017 May;112(3):32. doi: 10.1007/s00395-017-0619-0. Epub 2017 Apr 24. Review.

3.

A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor.

Kerr AG, Tam LCS, Hale AB, Cioroch M, Douglas G, Agkatsev S, Hibbitt O, Mason J, Holt-Martyn J, Bataille CJR, Wynne GM, Channon KM, Russell AJ, Wade-Martins R.

J Pharmacol Exp Ther. 2017 Jun;361(3):417-428. doi: 10.1124/jpet.116.239574. Epub 2017 Mar 30.

4.

PCSK9 and Atherosclerosis - Lipids and Beyond.

Shapiro MD, Fazio S.

J Atheroscler Thromb. 2017 May 1;24(5):462-472. doi: 10.5551/jat.RV17003. Epub 2017 Mar 9.

5.

PCSK9 inhibitors: A new era of lipid lowering therapy.

Chaudhary R, Garg J, Shah N, Sumner A.

World J Cardiol. 2017 Feb 26;9(2):76-91. doi: 10.4330/wjc.v9.i2.76. Review.

6.

Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice.

Rong S, Cortés VA, Rashid S, Anderson NN, McDonald JG, Liang G, Moon YA, Hammer RE, Horton JD.

Elife. 2017 Feb 28;6. pii: e25015. doi: 10.7554/eLife.25015.

7.

Modulation of cholesterol transport by maternal hypercholesterolemia in human full-term placenta.

Zhang R, Dong S, Ma WW, Cai XP, Le ZY, Xiao R, Zhou Q, Yu HL.

PLoS One. 2017 Feb 15;12(2):e0171934. doi: 10.1371/journal.pone.0171934. eCollection 2017.

8.

The Relationship Between Coronary Artery Disease and Genetic Polymorphisms of Melanoma Inhibitory Activity 3.

Zaimkohan H, Keramatipour M, Mirhafez SR, Tavakkoly-Bazzaz J, Tahooni A, Piryaei M, Ghayour-Mobarhan M, Ghaderian SM.

Iran Red Crescent Med J. 2016 Feb 13;18(9):e31146. doi: 10.5812/ircmj.31146. eCollection 2016 Sep.

9.

Differential proteomics profiling identifies LDPs and biological functions in high-fat diet-induced fatty livers.

Liu M, Ge R, Liu W, Liu Q, Xia X, Lai M, Liang L, Li C, Song L, Zhen B, Qin J, Ding C.

J Lipid Res. 2017 Apr;58(4):681-694. doi: 10.1194/jlr.M071407. Epub 2017 Feb 8.

10.

PCSK9 targets important for lipid metabolism.

Schulz R, Schlüter KD.

Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):2-11. doi: 10.1007/s11789-017-0085-0. Review.

11.

Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody.

Hansen RJ, Berna MJ, Sperry AE, Beyer TP, Wroblewski VJ, Schroeder KM, Eacho PI.

MAbs. 2017 Feb/Mar;9(2):285-296. doi: 10.1080/19420862.2016.1270490.

12.

Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.

Lebeau P, Al-Hashimi A, Sood S, Lhoták Š, Yu P, Gyulay G, Paré G, Chen SR, Trigatti B, Prat A, Seidah NG, Austin RC.

J Biol Chem. 2017 Jan 27;292(4):1510-1523. doi: 10.1074/jbc.M116.744235. Epub 2016 Dec 1.

PMID:
27909053
14.

Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL.

Cardiovasc Res. 2016 Oct;112(1):429-42. doi: 10.1093/cvr/cvw194. Epub 2016 Aug 5. Review.

PMID:
27496869
15.

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, Schumacher VA, Scherer PE, Salant DJ, Biddinger SB.

Circulation. 2016 Jul 5;134(1):61-72. doi: 10.1161/CIRCULATIONAHA.115.020912.

PMID:
27358438
16.

Effects of LDL Receptor Modulation on Lymphatic Function.

Milasan A, Dallaire F, Mayer G, Martel C.

Sci Rep. 2016 Jun 9;6:27862. doi: 10.1038/srep27862.

17.

Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor.

Topchiy E, Cirstea M, Kong HJ, Boyd JH, Wang Y, Russell JA, Walley KR.

PLoS One. 2016 May 12;11(5):e0155030. doi: 10.1371/journal.pone.0155030. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0160326.

18.

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, Devay RM, Liang H, Rashid S, Linton MF, Fazio S.

Cardiovasc Res. 2016 May 15;110(2):268-78. doi: 10.1093/cvr/cvw053. Epub 2016 Mar 15.

19.

Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics.

An D, Wei X, Li H, Gu H, Huang T, Zhao G, Liu B, Wang W, Chen L, Ma W, Zhang H, Cao S, Yuan Z.

Sci Rep. 2015 Dec 22;5:17559. doi: 10.1038/srep17559.

20.

Serum Lipoproteins Are Critical for Pulmonary Innate Defense against Staphylococcus aureus Quorum Sensing.

Manifold-Wheeler BC, Elmore BO, Triplett KD, Castleman MJ, Otto M, Hall PR.

J Immunol. 2016 Jan 1;196(1):328-35. doi: 10.4049/jimmunol.1501835. Epub 2015 Nov 25.

Supplemental Content

Support Center